Eight randomized trials have demonstrated a significantly higher tumor response rate and longer progression‐free survival (PFS) in EGFR‐mutant patients treated with first‐line TKI 1, 2, 3, 4, 5, 6, 7, 8. Here, EGFR is linked to neoplasm.